News | May 14, 2015

Combined Blood Pressure and LDL Cholesterol-Lowering Medication Therapy Reduces Harmful Coronary Plaque

Both standard and aggressive treatment provide similar benefit in reducing atherosclerosis

blood pressure, LDL, medication therapy, coronary plaque, SCAI

May 14, 2015 — Combining statins for low-density lipoprotein (LDL) and calcium channel antagonists for blood pressure reduces harmful coronary plaque, according to a study presented at the Society of Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego. The study, presented as a late-breaking clinical trial, found aggressive medication therapy does not provide additional benefit compared to standard cholesterol and blood pressure-lowering therapy.

Recent studies have separately shown aggressive treatment of LDL cholesterol with statins and blood pressure control with calcium channel antagonists can control the progression of, or reduce, coronary atherosclerosis. The MILLION study is the first multicenter study to evaluate both strategies simultaneously.

"Aggressively treating cholesterol and blood pressure levels have separately been shown to benefit patients with heart disease, so our study was designed to evaluate whether combined therapy with aggressive or standard targets for reducing LDL cholesterol and blood pressure would provide additional benefit," said Masa-aki Kawashiri, M.D., associate professor of medicine in the Division of Cardiovascular Medicine at Kanazawa University in Kanazawa, Japan, and a study investigator.

Researchers evaluated treatment in a total of 68 patients, including 33 patients who received standard therapy (focused on achieving LDL levels of 100 mg/dL and blood pressure below 140/90 mmHg) and 35 patients treated with aggressive therapy (focused on reducing LDL to 70 mg/dL and blood pressure to 120/70 mmHg). Prior to the study, all of the patients were treated successfully with percutaneous coronary intervention (PCI), and LDL levels greater than 100 mg/dL and had at least one additional coronary artery blockage in addition to the blockage treated by PCI.

Each patient underwent intravascular ultrasonography (IVUS) to measure vessel and plaque volume. After 18-24 months of treatment with blood pressure and cholesterol-lowering medications, follow-up IVUS was conducted. Patients in both groups reached their target blood pressure and LDL levels at the time of follow-up.

The study found both groups had similar rates of reduction in coronary plaque volume. The standard treatment group saw coronary plaque reduced by 9.37 percent while the aggressive group saw an 8.74 percent decrease, on average. However, patients treated with aggressive medication therapy saw more significant decreases in blood pressure (7.5/9.5 mmHg decrease) and LDL cholesterol (6.1 mg/dL decrease) compared with patients receiving standard treatment.

"Patients benefit from similar levels of coronary plaque volume reduction with the standard therapy as with more aggressive treatment," said Kawashiri. "Aggressive LDL cholesterol and blood pressure medication treatment does not provide additional benefit in reducing atherosclerosis. Combined therapy aimed at standard LDL and blood pressure targets provides similar benefit as more aggressive treatment."

Kawashiri reported their study group received research grants from Pfizer Ltd.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init